Skip to main content
. Author manuscript; available in PMC: 2006 May 30.
Published in final edited form as: J Am Coll Surg. 2004 May;198(5):685–696. doi: 10.1016/j.jamcollsurg.2004.01.025

Table 3.

Duration of Response in Patients with Metastatic Cancer Treated Using High-Dose Bolus Interleukin-2

Diagnosis Complete regression, mo. Partial regression, mo.
Melanoma 211+, 160+, 158+, 156+, 35, 319, 19, 10, 10,
154+, 147+, 143+, 134+, 8, 8, 7, 7, 6, 5, 5,
134+, 133+, 16, 12 5, 4, 4, 2
Renal cell
cancer 197+ , 186+ , 157+ , 157+ , 52, 30, 30, 22, 20,
153+ , 149+ , 149+ , 142+ , 17, 16, 15, 14, 14,
140+ , 133+ , 127+ , 126 + , 13, 11, 9, 8, 8, 7,
123+ , 112+ , 102+ , 87+ , 7, 6, 4, 4, 4, 4
46+ , 35, 23, 19, 19

“+” indicates ongoing response, as of June 1, 2003.

Of 33 patients with complete response, 27 remain in complete regression at 46 to 211 mo.